JP6894372B2 - カフェインの制御放出 - Google Patents
カフェインの制御放出 Download PDFInfo
- Publication number
- JP6894372B2 JP6894372B2 JP2017531594A JP2017531594A JP6894372B2 JP 6894372 B2 JP6894372 B2 JP 6894372B2 JP 2017531594 A JP2017531594 A JP 2017531594A JP 2017531594 A JP2017531594 A JP 2017531594A JP 6894372 B2 JP6894372 B2 JP 6894372B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- caffeine
- oil
- phase
- inverse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 title claims description 162
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 title claims description 81
- 229960001948 caffeine Drugs 0.000 title claims description 81
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 title claims description 81
- 238000013270 controlled release Methods 0.000 title claims description 7
- 239000000203 mixture Substances 0.000 claims description 98
- 239000003921 oil Substances 0.000 claims description 44
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 40
- 239000004530 micro-emulsion Substances 0.000 claims description 35
- 150000003904 phospholipids Chemical class 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 229940087305 limonene Drugs 0.000 claims description 21
- 235000001510 limonene Nutrition 0.000 claims description 20
- 150000002632 lipids Chemical class 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 17
- 239000002775 capsule Substances 0.000 claims description 11
- 239000000341 volatile oil Substances 0.000 claims description 11
- 230000037007 arousal Effects 0.000 claims description 10
- 206010041349 Somnolence Diseases 0.000 claims description 8
- 239000010635 coffee oil Substances 0.000 claims description 8
- 239000000693 micelle Substances 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 4
- 206010062519 Poor quality sleep Diseases 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010033307 Overweight Diseases 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 claims description 2
- 230000037213 diet Effects 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 238000005265 energy consumption Methods 0.000 claims 1
- 239000012071 phase Substances 0.000 description 52
- 235000019198 oils Nutrition 0.000 description 39
- 238000009792 diffusion process Methods 0.000 description 26
- 238000000235 small-angle X-ray scattering Methods 0.000 description 15
- 239000008346 aqueous phase Substances 0.000 description 14
- 230000002441 reversible effect Effects 0.000 description 14
- 238000013268 sustained release Methods 0.000 description 11
- 239000012730 sustained-release form Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 239000004973 liquid crystal related substance Substances 0.000 description 7
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 150000003505 terpenes Chemical class 0.000 description 6
- 235000007586 terpenes Nutrition 0.000 description 6
- 244000273928 Zingiber officinale Species 0.000 description 5
- 235000006886 Zingiber officinale Nutrition 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000008397 ginger Nutrition 0.000 description 5
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 3
- 235000006008 Brassica napus var napus Nutrition 0.000 description 3
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 3
- 244000188595 Brassica sinapistrum Species 0.000 description 3
- 240000004784 Cymbopogon citratus Species 0.000 description 3
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 244000004281 Eucalyptus maculata Species 0.000 description 3
- 240000007926 Ocimum gratissimum Species 0.000 description 3
- 240000002657 Thymus vulgaris Species 0.000 description 3
- 235000007303 Thymus vulgaris Nutrition 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000001585 thymus vulgaris Substances 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 235000010676 Ocimum basilicum Nutrition 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 240000004760 Pimpinella anisum Species 0.000 description 2
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 2
- 244000223014 Syzygium aromaticum Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- 235000009499 Vanilla fragrans Nutrition 0.000 description 2
- 244000263375 Vanilla tahitensis Species 0.000 description 2
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 2
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 2
- 230000036626 alertness Effects 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 229930004069 diterpene Natural products 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- -1 limonene Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000005297 pyrex Substances 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- 238000001464 small-angle X-ray scattering data Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 240000000662 Anethum graveolens Species 0.000 description 1
- 235000003099 Artemisia herba alba Nutrition 0.000 description 1
- 241001249229 Artemisia herba-alba Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 241000208152 Geranium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000208818 Helianthus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 235000013628 Lantana involucrata Nutrition 0.000 description 1
- 240000005183 Lantana involucrata Species 0.000 description 1
- 244000165082 Lavanda vera Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 1
- 235000004066 Ocimum gratissimum Nutrition 0.000 description 1
- 235000002725 Olea europaea Nutrition 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 241000533293 Sesbania emerus Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000234314 Zingiber Species 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000222 aromatherapy Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 235000012174 carbonated soft drink Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940087559 grape seed Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000010657 mentha arvensis oil Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 235000010204 pine bark Nutrition 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- AQRYNYUOKMNDDV-UHFFFAOYSA-M silver behenate Chemical compound [Ag+].CCCCCCCCCCCCCCCCCCCCCC([O-])=O AQRYNYUOKMNDDV-UHFFFAOYSA-M 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 239000007886 soft shell capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F5/00—Coffee; Coffee substitutes; Preparations thereof
- A23F5/10—Treating roasted coffee; Preparations produced thereby
- A23F5/12—Agglomerating, flaking or tabletting
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F5/00—Coffee; Coffee substitutes; Preparations thereof
- A23F5/24—Extraction of coffee; Coffee extracts; Making instant coffee
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Animal Husbandry (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Anesthesiology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Dispersion Chemistry (AREA)
Description
覚醒させる、かつ/又は睡魔と闘うために、様々な刺激物が人に投与され得ることはよく知られている。こうした目的に使用される典型的な刺激物はカフェインである。好都合なことに、カフェインはコーヒー、お茶、及び一部の炭酸清涼飲料などの飲料中に見いだされる。カフェインを投与する最も一般的な形態の一つは、一日を始めるときに人がより覚醒するのに役立つようにと早朝に1杯のホットコーヒーを飲むことである。
本発明は第1の態様において、25℃で液体である脂質連続相と、自己組織化構造とを有する食用組成物であって、油、リン脂質、カフェイン及び水を含む組成物を提供する。本発明のある態様では、食用組成物は、眠気の処置又は予防において使用するためのものである。
ダイズ豆ホスファチジルコリン(PC)は、Epikuron200という製品名でCargill(Germany)から購入した。(R)−(+)−リモネン及びカフェインは、Sigma−Aldrichから購入した。Pyrex試験管中で、以下の組成で中間相(0.3g)を調製した:
(式中、Qは中間相の表面S(S≒0.9cm2)を通過する薬物のモル流束であり、C0は中間相中のカフェインの初期モル濃度であり、tは放出時間である)。拡散係数上のエラーバーは、非線形方程式についての誤差伝播法によって計算した:
ダイズ豆ホスファチジルコリン(Epikuron200)、(R)−(+)−リモネン及びカフェインを実施例1のように用いたが、以下の実験では異なるパーセンテージのコーヒー油を添加した。
Pyrex試験管中で、以下の組成で中間相(0.3g)を調製した:
Claims (13)
- 25℃で液体である脂質連続相と、自己組織化構造とを有する食用組成物であって、油、リン脂質、カフェイン及び水を含む、組成物であって、
前記組成物中に含まれる前記油が精油を含み、前記精油がコーヒー油及びリモネンを含む、組成物。 - 油の重量が油及びリン脂質の総重量の1%より多い、請求項1に記載の組成物。
- 前記自己組織化構造が、逆L2相、逆マイクロエマルション、逆ミセルキュービック構造、逆双連続キュービック構造、逆スポンジ相、逆ヘキサゴナル構造、ラメラ相及びこれらの組合せからなる群から選択される構造である、請求項1又は2に記載の組成物。
- 眠気又は覚醒障害の処置又は予防において使用するための、請求項1〜3のいずれか一項に記載の組成物。
- 前記組成物が、高齢対象への投与用である、請求項4に記載の組成物。
- 対象がヒト又は愛玩動物である、請求項4又は5に記載の組成物。
- 肥満又は過体重の処置又は予防において使用するための、請求項1〜3のいずれか一項に記載の組成物。
- 前記組成物が、1kg体重あたり0.5mg〜10mgのカフェインを提供するような一日量で投与される、請求項4〜7のいずれか一項に記載の組成物。
- 意識の覚醒を高めるための、請求項1〜3のいずれか一項に記載の組成物の非治療的使用。
- 食事誘発性熱産生及びエネルギー消費を高めるための、請求項1〜3のいずれか一項に記載の組成物の非治療的使用。
- カフェインの制御放出をもたらすための、請求項1〜3のいずれか一項に記載の組成物の使用。
- 請求項1〜3のいずれか一項に記載の組成物を含む食用カプセル。
- 前記食用カプセルが栄養補助食品である、請求項12に記載の食用カプセル。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14198056.5 | 2014-12-15 | ||
EP14198056 | 2014-12-15 | ||
PCT/EP2015/078591 WO2016096468A1 (en) | 2014-12-15 | 2015-12-03 | Controlled release of caffeine |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018509136A JP2018509136A (ja) | 2018-04-05 |
JP6894372B2 true JP6894372B2 (ja) | 2021-06-30 |
Family
ID=52146148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017531594A Expired - Fee Related JP6894372B2 (ja) | 2014-12-15 | 2015-12-03 | カフェインの制御放出 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11096897B2 (ja) |
EP (1) | EP3232813B1 (ja) |
JP (1) | JP6894372B2 (ja) |
CN (1) | CN106998744A (ja) |
WO (1) | WO2016096468A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210169820A1 (en) | 2019-09-12 | 2021-06-10 | Nulixir Inc. | Controlled release concentrate and suspensions including the same |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995011595A1 (en) | 1993-10-28 | 1995-05-04 | Ajinomoto General Foods, Inc. | Method for treating coffee aromas |
US7115297B2 (en) * | 2000-02-22 | 2006-10-03 | Suzanne Jaffe Stillman | Nutritionally fortified liquid composition with added value delivery systems/elements/additives |
US6475530B1 (en) | 2000-05-31 | 2002-11-05 | Eric H. Kuhrts | Methods and compositions for producing weight loss |
GB0101198D0 (en) | 2001-01-17 | 2001-02-28 | Scherer Technologies Inc R P | Ingestible compositions containing an odoriferous oil |
US20040156816A1 (en) * | 2002-08-06 | 2004-08-12 | David Anderson | Lipid-drug complexes in reversed liquid and liquid crystalline phases |
JP2004147578A (ja) * | 2002-10-31 | 2004-05-27 | Ucc Ueshima Coffee Co Ltd | 芳香化されたコーヒーオイルの製造方法 |
EP1504671A1 (en) * | 2003-07-30 | 2005-02-09 | Nestec S.A. | Controlled delivery of caffeine from high-caffeinated coffee beverages made from soluble powder |
EP1598060A1 (en) * | 2004-05-18 | 2005-11-23 | Nestec S.A. | Oil-in-water emulsion for delivery |
RU2417618C2 (ru) * | 2005-11-22 | 2011-05-10 | Нестек С.А. | Способ приготовления эмульсии масло-в-воде, эмульсия масло-в-воде и легко диспергируемая липидная фаза для нее, набор для получения указанной эмульсии (варианты) |
BRPI0618870A2 (pt) * | 2005-11-22 | 2011-09-13 | Nestec Sa | emulsão de óleo-em-água e seu uso para a distribuição de funcionalidade |
US20080171085A1 (en) * | 2007-01-11 | 2008-07-17 | Natrol, Inc. | Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration |
RU2505067C2 (ru) * | 2008-06-24 | 2014-01-27 | Нестек С.А. | Вкусовая композиция майяра (варианты) и способ приготовления таких композиций |
US8043645B2 (en) * | 2008-07-09 | 2011-10-25 | Starbucks Corporation | Method of making beverages with enhanced flavors and aromas |
JP5620647B2 (ja) * | 2009-01-30 | 2014-11-05 | ハウス食品グループ本社株式会社 | 眠気覚まし用組成物 |
JP5833846B2 (ja) * | 2011-06-30 | 2015-12-16 | サントリー食品インターナショナル株式会社 | 植物精油の分離方法 |
CN105228470B (zh) | 2013-03-15 | 2019-05-31 | 维尔恩公司 | 维生素e水溶性衍生物制剂及包含其的组合物 |
-
2015
- 2015-12-03 EP EP15804778.7A patent/EP3232813B1/en active Active
- 2015-12-03 JP JP2017531594A patent/JP6894372B2/ja not_active Expired - Fee Related
- 2015-12-03 US US15/535,836 patent/US11096897B2/en active Active
- 2015-12-03 WO PCT/EP2015/078591 patent/WO2016096468A1/en active Application Filing
- 2015-12-03 CN CN201580065656.4A patent/CN106998744A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
CN106998744A (zh) | 2017-08-01 |
EP3232813B1 (en) | 2021-01-20 |
US20170367984A1 (en) | 2017-12-28 |
WO2016096468A1 (en) | 2016-06-23 |
US11096897B2 (en) | 2021-08-24 |
JP2018509136A (ja) | 2018-04-05 |
EP3232813A1 (en) | 2017-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Davidov-Pardo et al. | Nutraceutical delivery systems: Resveratrol encapsulation in grape seed oil nanoemulsions formed by spontaneous emulsification | |
Pengon et al. | The effect of surfactant on the physical properties of coconut oil nanoemulsions | |
Aziz et al. | Enrichment of Eucalyptus oil nanoemulsion by micellar nanotechnology: Transdermal analgesic activity using hot plate test in rats’ assay | |
Zhu et al. | In vitro and in vivo evaluation of capsaicin‐loaded microemulsion for enhanced oral bioavailability | |
CN105792660B (zh) | 采用可食用无机盐颗粒进行稳定的乳剂 | |
Satapathy et al. | Sunflower‐oil‐based lecithin organogels as matrices for controlled drug delivery | |
BR112019012309A2 (pt) | flocos secos com ingredientes ativos | |
Moghimipour et al. | Formulation and evaluation of liposomes for transdermal delivery of celecoxib | |
Harwansh et al. | Nanoemulsions as vehicles for transdermal delivery of glycyrrhizin | |
Chaiyana et al. | Characterization of potent anticholinesterase plant oil based microemulsion | |
Ni et al. | Nanoemulsions‐based delivery systems for encapsulation of quercetin: Preparation, characterization, and cytotoxicity studies | |
JP2006016312A (ja) | 脂肪代謝改善組成物 | |
Kalaitzaki et al. | Biocompatible nanodispersions as delivery systems of food additives: A structural study | |
JP6894372B2 (ja) | カフェインの制御放出 | |
EP2214687A1 (en) | Nutraceutical compositions containing whole-fruit zanthoxylum bungeanum extract | |
TW200838496A (en) | Agent for alleviating or preventing stress symptoms and agent for improving mental conditions | |
CN106728564A (zh) | 提神醒脑组合物及其制剂 | |
WO2010002406A1 (en) | Compositions comprising rhodiola rosea and methods of use thereof | |
WO2008061756A1 (en) | Dietary and pharmaceutical compositions comprising a sage extract containing a mixture of tricyclic diterpenes and their derivatives and their uses | |
KR20180050331A (ko) | 증가된 안정성 및 개선된 흡수율을 갖는 호노키올 및 마그놀롤 제형, 및 이의 사용 방법 | |
Kalita et al. | Resveratrol-phospholipid complexes (phytosomes) with improved physicochemical properties favorable for drug delivery via skin | |
Fauziah et al. | Effect of Ethyl Acetate Extract of Penicillium citrinum from Xestopongia testudinaria on Blood Glucose Level, Insulin Concentration, and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR). | |
US20100003351A1 (en) | Compositions comprising rhodiola rosea and methods of use thereof | |
BOANCA et al. | The effects of magnesium nanovesicle formulations on spatial memory performance in mice | |
Klu et al. | Quantitative estimation of the caffeine content in some energy drinks on the Ghanaian market |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181120 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20190614 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190823 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190903 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191122 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200512 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210119 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210412 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210525 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210603 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6894372 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |